Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Usana Health SciencesUSNA -1.25%66 Return-on-Tangible-Asset is 5.90% as of Mar. 2026, which is 66% below its 10-year median of 17.35. GuruFocus rates USNA with a GF Score™ of 66/100 and a GF Value™ of $41.43 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,996 Consumer Packaged Goods companies, Usana Health Sciences ranks worse than 61.27% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Usana Health Sciences's annualizedNet Income for the quarter that ended in Mar. 2026 was $27.8 Mil. Usana Health Sciences's average total tangible assets for the quarter that ended in Mar. 2026 was $471.9 Mil. Therefore, Usana Health Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 5.90%.
The historical rank and industry rank for Usana Health Sciences's Return-on-Tangible-Asset or its related term are showing as below:
USNA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.82 Med: 17.35 Max: 25.96
Current: 1.82
During the past 13 years, Usana Health Sciences's highest Return-on-Tangible-Asset was 25.96%. The lowest was 1.82%. And the median was 17.35%.
USNA's Return-on-Tangible-Asset is ranked worse than 61.27% of 1996
companies
in the Consumer Packaged Goods industry
Industry Median: 3.395
vs USNA: 1.82
Usana Health Sciences (NYSE:USNA) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Usana Health Sciences Return-on-Tangible-Asset Related Terms
Usana Health Sciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Usana Health Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Usana Health Sciences Return-on-Tangible-Asset Chart
USNA vs NATR, ENHA, BYND: Return-on-Tangible-Asset Comparison
For the Packaged Foods subindustry, Usana Health Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Usana Health Sciences Return-on-Tangible-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 5.90% mean?
Usana Health Sciences (USNA) has a Return-on-Tangible-Asset of 5.90% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Usana Health Sciences and its competitors. This is 66% below median its historical median of 17.35. Over the past decade, Usana Health Sciences' Return-on-Tangible-Asset has ranged from 1.82 to 25.96. According to the industry distribution chart, Usana Health Sciences ranks #1223 out of 1996 companies in the Consumer Packaged Goods industry, placing it in the top 61.3%.
Is Usana Health Sciences' Return-on-Tangible-Asset too high?
Usana Health Sciences' current Return-on-Tangible-Asset of 5.90% is 66% below median its 10-year median of 17.35. Over the past 10 years, this metric has ranged from a low of 1.82 to a high of 25.96. The Consumer Packaged Goods industry median Return-on-Tangible-Asset is 3.40. Usana Health Sciences' value of 5.90% is 73.8% above this industry median. Based on the distribution chart, Usana Health Sciences ranks #1223 out of 1996 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Usana Health Sciences has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' Return-on-Tangible-Asset compare to NATR and ENHA?
According to the Consumer Packaged Goods industry distribution chart, Usana Health Sciences ranks #1223 out of 1996 companies for Return-on-Tangible-Asset. This places Usana Health Sciences in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.40. Usana Health Sciences' value of 5.90% is 73.8% above this benchmark. Historically, Usana Health Sciences' own Return-on-Tangible-Asset has ranged from 1.82 to 25.96 over the past decade. While the company's 10-year median is 17.35 vs. the industry median of 3.40, Usana Health Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Consumer Packaged Goods company?
The median Return-on-Tangible-Asset among Consumer Packaged Goods companies is 3.40, based on 1,996 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Usana Health Sciences's current Return-on-Tangible-Asset of 5.90% is 73.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Usana Health Sciences and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Asset is 3.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Usana Health Sciences's current Return-on-Tangible-Asset is 5.90%, which is 66% below median its own 10-year median of 17.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (USNA) is currently considered Possible Value Trap. The stock's GF Value™ is $41.43, compared to a current price of $22.12 — trading 46.6% below its estimated fair value. The current Return-on-Tangible-Asset is 5.90%, which is 66% below median its 10-year median of 17.35 and 73.8% above the Consumer Packaged Goods industry median of 3.40. Usana Health Sciences' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Usana Health Sciences (USNA), the current Return-on-Tangible-Asset is 5.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Usana Health Sciences (USNA) Overvalued in 2026?
Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued.
The current stock price of $22.12 is trading 46.6% below its estimated GF Value™ of $41.43.
GuruFocus considers Usana Health Sciences to be Possible Value Trap.
Key valuation signals for USNA:
Return-on-Tangible-Asset: 5.90% (66% below median its 10-year median of 17.35)
GF Value™: $41.43 vs. price of $22.12 (46.6% below fair value)
Industry Position: 73.8% above the Consumer Packaged Goods median (#1223 of 1996)
No single metric tells the full story. See the USNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
66GF Score
Get the complete analysis for USNA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
USNA has been successfully added to your 
